Management of Neutropenia in Chronic Myeloid Leukemia

Initial Assessment and Monitoring

The National Comprehensive Cancer Network recommends that for Grade 3-4 neutropenia (ANC <1000/mm³) in chronic phase CML patients on TKI therapy, the drug should be held until ANC ≥1500/mm³, then resumed at the original dose; if neutropenia recurs, the drug should be held again until ANC ≥1500/mm³ and resumed at a reduced dose 1, 2
Blood counts should be monitored weekly for the first 4-6 weeks of TKI treatment, then every 2 weeks or monthly until month 3, and subsequently every 3 months in chronic phase 3, 4
More frequent monitoring is required for patients with advanced disease 3

For imatinib, the American College of Hematology recommends stopping the drug until ANC ≥1500/mm³, then resuming at the starting dose of 400 mg daily for the first episode of ANC <1000/mm³ 1, 2
For imatinib, the American College of Hematology recommends stopping the drug until ANC ≥1500/mm³, then resuming at a reduced dose of 300 mg daily for recurrent episodes of ANC <1000/mm³ 1, 2
For dasatinib, the European Society for Medical Oncology recommends stopping the drug until ANC ≥1000/mm³, then resuming at the original starting dose for the first episode of ANC <500/mm³ 3
For dasatinib, the European Society for Medical Oncology recommends stopping the drug until ANC ≥1000/mm³, then resuming at a reduced dose of 80 mg once daily for the second episode of ANC <500/mm³ 3

For accelerated or blast phase CML, the National Comprehensive Cancer Network recommends reducing imatinib dose to 400 mg if cytopenia is unrelated to disease 1, 2
For accelerated or blast phase CML, the National Comprehensive Cancer Network recommends reducing imatinib dose further to 300 mg if cytopenia persists 2 weeks 1, 2
Consider bone marrow examination to differentiate disease persistence from hypocellularity 3, 5

The American Society of Clinical Oncology recommends using G-CSF (filgrastim) for resistant neutropenia, as it can be used in combination with TKIs for patients with resistant neutropenia 1, 2
The European Society for Medical Oncology recommends that the concomitant use of G-CSF with TKIs is effective and does not appear to be associated with lower response rates or TKI failure 3, 5

For chronic phase patients on first-line TKI, the Infectious Diseases Society of America recommends withholding therapy and treating infection appropriately with antibiotics for Grade 3 febrile neutropenia, and resuming at a lower dose when the grade resolves to <3 5
For second-line or advanced phase patients, the National Comprehensive Cancer Network recommends using stepwise dose lowering rather than immediate TKI switch, as switching options may be limited 5

The American College of Hematology recommends not continuing full-dose TKI through severe neutropenia (ANC <1000/mm³) in chronic phase, as this increases infection risk without clear benefit 1, 2
The European Society for Medical Oncology recommends considering that myelosuppression is often an expression of TKI efficacy rather than true toxicity, and typically becomes rare once remission is achieved 4
The National Comprehensive Cancer Network recommends avoiding unnecessary antimicrobial prophylaxis in mild cases of leukopenia to prevent antibiotic resistance 4

The American Society of Clinical Oncology recommends considering switching to an alternative TKI if neutropenia persists despite dose reductions and G-CSF support 4
The European Society for Medical Oncology recommends considering switching to an alternative TKI if bone marrow examination shows hypocellularity rather than disease persistence 3, 5
The National Comprehensive Cancer Network recommends considering switching to an alternative TKI if the patient experiences recurrent febrile neutropenia requiring multiple treatment interruptions 5